December 2, 2014: UAS Labs Acquires Micropharma and Cardioviva™ Probiotics
UAS Laboratories LLC (Wausau, Wisconsin, USA) is pleased to announce the acquisition of certain intellectual property assets of Micropharma Limited, Montreal, Canada, whose brilliant researchers have skillfully developed the award-winning probiotic strain, Lactobacillus reuteri NCIMB 30242 offered under the mark LRC™ and protected by two families of registered patents. The LRC™ strain has been shown to support healthy cholesterol levels and maintain heart health. As part of the agreement, UAS Labs also takes ownership of the pioneering Cardioviva™ brand of probiotics; formulations offered under the Cardioviva™ brand can be found at major retailers in the US and Canada.
The companies have enjoyed a close relationship as partners and industry leaders in the probiotic space and were both winners of the 2014 NEXT Innovation Summit’s NutraAward presented at Natural Products Expo West. Micropharma accepted the best new ingredient award for the L. reuteri strain NCIMB 30242 which is backed by multiple gold standard human clinical trials. UAS Labs is proud to add this well-researched strain to their impressive portfolio which boasts the famous strain, Lactobacillus acidophilus DDS®-1.
UAS Labs President and CEO, Kevin Mehring states, “We are extremely proud to have acquired this superb intellectual property from Micropharma as it furthers our company mission of being the leader in providing probiotic-based health solutions worldwide and for growing the condition-specific health benefits associated with these bacteria.”
Dr. Gregory Leyer, Chief Scientific Officer for UAS Labs continues, “The founders and employees at Micropharma have set the industry standard for taking a probiotic strain through the discovery and commercialization process. We are honored to have the opportunity to write the next successful chapter for this strain, brand and ultimately the emerging heart health category for probiotics.”
Micropharma CEO Ryan Jones is excited as well to witness this next stage, “UAS Labs and its experienced management team are perfectly positioned to advance not only the commercial success but also the scientific documentation around the LRC™ strain and the Cardioviva™ formulations.
Lakeview Equity Partners, LLC, the majority owner of UAS Labs, provided funding to complete this acquisition and the recently completed $4 million state-of-the-art upgrade to their probiotic focused manufacturing facility in central Wisconsin. This upgrade positions UAS Labs to continue to grow as an industry leader in probiotics.
About UAS Laboratories
Founded in 1979, UAS Labs has delivered the highest quality, science-backed probiotics to the natural products marketplace for more than thirty years. Strictly dedicated to probiotic manufacturing, UAS is committed to designing innovative and effective formulations including strains such as L. acidophilus DDS®-1.
Montreal-based Micropharma Limited discovers and develops therapeutics, diagnostics and devices based on the emerging science of the human microbiome and its environment. The company applies a unique approach to discover novel and commercial probiotic and enzymatic solutions for metabolic diseases.
About Lakeview Equity Partners, LLC
Lakeview Equity Partners is a private equity investment fund that focuses on investments in Midwest-based, middle market companies. Lakeview Equity’s mission is to identify and invest in strong, well-managed companies to help them achieve continued growth and profitability and support ownership change, including ownership opportunities for managers and employees.